Loading
Alphamab Oncology
Alphamab developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003.
Also called: 康宁杰瑞Jiangsu Alphamab BiopharmaceuticalsAlphamab Oncology
Overview
Alphamab Oncology, based in Suzhou, founded in 2008 and listed in Hong Kong as 9966.HK, developed envafolimab, the first subcutaneous PD-L1 antibody approved anywhere, and the HER2 bispecific ADC JSKN003. Envafolimab, sold as Enweida, was approved in 2021; KN026, a HER2 biparatopic bispecific, is in phase 3 in gastric and breast cancer; and JSKN003 and JSKN033, a subcutaneous PD-L1 plus HER2 ADC combination, are in trials, all built on its single-domain antibody platform. OnCo links it to HER2 and PD-L1 as targets and to the envafolimab record. Whether subcutaneous dosing wins meaningful share in a class dominated by intravenous antibodies is the open question. Envafolimab has its own page.
Headquarters
Suzhou, CN
Scorecard
All companies#134of 1245 companies, score 43
- approved products +6
- phase 3 +6
- targets +6
- modalities +4
- regions +1
- registry trials +20
1 approved, 2 in phase 3, 0 earlier, 3 targets, 104 registry studies. Formula on the scorecards page.
Type
Biotech · 9966.HK
Stage
Public
Website
Founded
2008
Products
3ApprovedSingle-domain antibody (anti-PD-L1, subcutaneous)
Envafolimab · Enweida
Envafolimab is the first PD-L1 antibody given as a quick injection under the skin rather than an infusion, approved in China for advanced tumours with mismatch-repair deficiency.
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
JSKN003 is an experimental investigational agent whose form is not stated in the registry from Jiangsu Alphamab Biopharmaceuticals in phase 3 trials for HR-positive / HER2-negative breast cancer and HER2-positive breast cancer, with its target not yet stated publicly.
Phase 3ADC
JSKN016 is an experimental drug that targets two proteins on cancer cells and carries chemotherapy. It has reached phase 3 testing; earlier response findings do not prove comparative benefit.
Connected
14Similar pages
- TreatmentSugemalimab
Shares PD-L1 and the tag china.
- CompanyCSPC Pharmaceutical Group
Shares JSKN003 and the tag china.
- TreatmentAdebrelimab
Shares PD-L1 and the tag china.
- TreatmentInetetamab
Shares HER2 and the tag china.
- TreatmentBenmelstobart
Shares PD-L1 and the tag china.
- TreatmentIparomlimab and tuvonralimab
Shares PD-L1 and the tag china.
- TrialKN035 for dMMR/MSI-H Advanced Solid Tumors
Shares 3D Medicines, Envafolimab.
- TrialENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors
Shares 3D Medicines, Envafolimab.
fronts
targets
drugs
ApprovedSingle-domain antibody (anti-PD-L1, subcutaneous)
Envafolimab · Enweida
Phase 3antibody-drug conjugate (ADC), per the sponsor's pipeline page; form not stated in the registry record
Phase 3ADC
companies
trials
A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung CancerA Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of CareEvaluation of JSKN016 in the Treatment of Advanced Non-small Cell Lung Cance： a Phase II Clinical StudyJSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsSafety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid TumorsStudy of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
alphamabonc.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/